XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - USD ($)
 12 Months Ended
May 29, 2022
Mar. 15, 2023
Nov. 29, 2020
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date May 29, 2022    
Document Transition Report false    
Entity File Number 000-27446    
Entity Registrant Name LIFECORE BIOMEDICAL, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 94-3025618    
Entity Address, Address Line One 3515 Lyman Boulevard    
Entity Address, City or Town Chaska,    
Entity Address, State or Province MN    
Entity Address, Postal Zip Code 55318    
City Area Code 952    
Local Phone Number 368-4300    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol LFCR    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status No    
Entity Interactive Data Current No    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 225,356,000
Entity Common Stock, Shares Outstanding   30,319,208  
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement relating to its 2022 Annual Meeting of Stockholders (the “Proxy Statement”) filed with the Securities and Exchange Commission on September 19, 2022, are incorporated herein by reference where indicated. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K/A, the Proxy Statement is not deemed to be filed as part hereof.    
Amendment Flag true    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001005286    
Current Fiscal Year End Date --05-29    
Amendment Description This Amendment No. 1 on Form 10-K/A (the “Amendment”) is being filed by Lifecore Biomedical, Inc. (f/k/a Landec Corporation) (the “Company”) to amend and restate its Annual Report on Form 10-K for the year ended May 29, 2022, originally filed with the Securities and Exchange Commission (the “SEC”) on September 14, 2022 (the “Original 10-K”, and, as amended by this Amendment, the “Annual Report”) to reflect the restatement of the Company’s audited consolidated financial statements as of and for the year ended May 29, 2022 contained in the Original 10-K (the “Restatement”). This Amendment also adjusts the report by Ernst & Young LLP, the Company’s Independent Registered Public Accounting Firm, that had appeared on page 39 of the Original 10-K. In addition, the Company is including in this Amendment currently dated certifications from its Chief Executive Officer and Chief Financial Officer as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, attached hereto as Exhibits 31.1 and 31.2 and Exhibits 32.1 and 32.2, respectively. The exhibits listed in Part IV-Item 15 “Exhibits and Financial Statement Schedules” are filed herewith in accordance with Rule 12b-15 of the Exchange Act.This Amendment also includes the Company’s determination that, as of the date of the filing of this Amendment, the date the accompanying consolidated financial statements are being re-issued (the “Amended Filing Date”), the existence of certain conditions and events raise substantial doubt about the Company’s ability to continue as a going concern within one year following the Amended Filing Date.